MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018

Successful progression of clinical projectsApril – JuneSignificant events during the quarter · Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met the primary endpoint, demonstrating that MIV-711 200mg had an acceptable safety and tolerability profile. · Preclinical data on MIV-818 were presented at the AACR Annual Meeting. · The design of the ongoing phase I/II study of birinapant in combination with Keytruda®, including the planned phase II dose expansion cohorts, was presented at the 2018 American Society for Clinical Oncology